QGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Qiagen NV (QGEN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown positive financial growth in Q4 2025 and has optimistic analyst price targets, the technical indicators and options data suggest a neutral to slightly bearish sentiment in the short term. Additionally, hedge funds are selling the stock, and there are no strong proprietary trading signals to support immediate action.
The MACD histogram is -0.36, indicating bearish momentum, while RSI is neutral at 47.933. Moving averages are converging, showing no clear trend. Key support is at $47.665, and resistance is at $51.355. The stock is trading pre-market at $49.08, slightly below the pivot point of $49.51, suggesting a lack of upward momentum.
Q4 2025 financials showed revenue growth of 3.69% YoY, net income growth of 22.09% YoY, and EPS growth of 28.95% YoY.
Analysts have raised price targets, with some projecting up to $
Options trading volume has exceeded the average daily volume, indicating active investor interest.
Hedge funds are selling the stock, with a 286.76% increase in selling activity over the last quarter.
Gross margin dropped by 6.94% YoY in Q4 2025, which could indicate cost pressures.
Technical indicators suggest a lack of strong upward momentum.
No recent congress trading data or influential figure activity to support confidence in the stock.
In Q4 2025, Qiagen reported revenue of $540.42M, up 3.69% YoY. Net income increased to $107.83M, up 22.09% YoY, and EPS rose to $0.49, up 28.95% YoY. However, gross margin declined to 59.77%, down 6.94% YoY, indicating potential cost pressures.
Analysts have mixed views on Qiagen. UBS, Stifel, and TD Cowen maintain neutral ratings with modest price target increases. JPMorgan, Barclays, and Jefferies have overweight or buy ratings, with price targets as high as $60. Deutsche Bank downgraded the stock to Hold, citing takeover speculation and fair valuation concerns.
